Beovu Drug Information
The drug is approved to treat people with an eye disorder called wet age-related macular degeneration (AMD), which is where blood vessels continuously grow beneath the retina, causing excess blood and fluid to leak. Beovu is designed to prevent these new blood vessels from forming under the retina – a sensory membrane inside the back lining of the eye. Wet AMD is a chronic eye disease that can lead to blurred vision and/or blind spots.
Beovu is typically administered once per month for 3 months, and then once every 8 to 12 weeks.
For a free legal consultation, call 877-562-0000
Unfortunately, many people who have turned to Beovu to help mitigate their wet AMD symptoms have been left in even worse condition. Beovu injections have proven to cause severe eye conditions such as retinal vasculitis and retinal vascular occlusion—a condition that causes retinal swelling, blurred vision, and blindness. The FDA confirmed these adverse events to be associated with Beovu.
One study showed that retinal vasculitis, retinal artery occlusion or severe vision loss occurred in 8.75 to 10.08 out of 10,000 Beovu injections. Initially, these potential side effects were not included on the Beovu product label.
Adverse reactions not listed by Novartis upon its release include:
- Retinal artery occlusion
- Retinal vascular occlusion
- Retinal vasculitis
- Retinal vein occlusion
Contact our personal injury lawyers today
Beovu Lawsuit Updates
On June 11, 2020, the Food and Drug Administration (FDA) approved an update of the product labels for Beovu to include warnings for adverse reactions such as the ones listed above. The drug, however, had already been in use for eight months, meaning tens of thousands of these shots had already been administered without any warning about retinal vasculitis or retinal vascular occlusion.
In December 2021, the Beovu drug label was updated in Europe, adding more information about these potential vision loss side effects, but not in the United States. Ultimately, Novartis again revised Beovu’s prescribing information nationwide in February 2022 to include even more detail about these risks. This was based on the results of additional clinical studies that independently confirmed the increased risk of retinal vasculitis and retinal vascular occlusion in patients receiving Beovu.
Complete a Free Case Evaluation form now
Have You Suffered After Receiving BEOVU® Injections?
If you or your loved one suffered from an adverse reaction listed above after receiving injections of the BEOVU® drug, then you may be able to pursue a class action personal injury lawsuit against Novartis.
At Cory Watson, our nationally recognized attorneys are actively investigating Beovu claims and working to secure the compensation you need. We will guide you through your legal options so that you can focus on your health and recovery.
Our qualified team of attorneys offers you a free case evaluation to determine if you are entitled to benefits for your specific case. Our personal injury law firm works on a contingency basis, meaning you pay nothing out of pocket unless we win your case.
Your health may be at risk, so please contact us now.